113082-39-6 Usage
General Description
2-chloro-6-methylquinazoline is an organic compound that belongs to the quinazoline family of chemicals. The compound is a derivative of quinazoline, which is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs. 2-chloro-6-methylquinazoline is specifically used in the production of pharmaceuticals and agrochemicals, and its chemical structure and properties make it valuable for the design and development of new drugs. Its derivatives have been found to exhibit a wide range of biological activities, including antimicrobial, antifungal, and anticancer properties. The chemical is also used in the synthesis of various heterocyclic compounds, which are important for the development of new drugs and agrochemicals. Overall, 2-chloro-6-methylquinazoline has significant applications in the pharmaceutical and agrochemical industries, making it a valuable compound for drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 113082-39-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,3,0,8 and 2 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 113082-39:
(8*1)+(7*1)+(6*3)+(5*0)+(4*8)+(3*2)+(2*3)+(1*9)=86
86 % 10 = 6
So 113082-39-6 is a valid CAS Registry Number.
113082-39-6Relevant articles and documents
AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS
-
Paragraph 00426; 00427, (2017/05/19)
The present invention relates to novel aminoisoxazoline compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.